Pricing & Market Access

A medicine-pricing policy that uses prices for the same or comparable product in other jurisdictions as benchmarks for a domestic price or reimbursement decision.

A list of medications approved for coverage by a health plan or system, often organised into tiers reflecting patient cost-sharing levels.

A pharmaceutical product with the same active ingredient as an approved brand-name drug, demonstrated bioequivalent and typically approved through an abbreviated pathway.

The practice of dispensing a generic drug in place of a prescribed brand-name product, typically permitted once a bioequivalent version is available.

The overall reduction from a drug's publicly listed gross price to the actual net price realised after rebates and discounts.

A pricing approach in which a single drug is priced differently depending on the medical condition, or indication, for which it is used.

A policy grouping therapeutically similar drugs and setting a single reference reimbursement level, requiring patients to pay any difference for pricier options.

The initial price at which a manufacturer introduces a new drug to a specific market, shaping both initial access and later reference pricing.